Company profile
Cipherx Technologies Ltd
CipherX | A New Era of Tattooing
Be your own tattoo artists and create custom tattoos with our easy-to-use online design tool. With our new microneedle technology, design and export a unique patch to apply safely at home.
Latest accounts
Financial period: 1 Oct 2024 to 30 Sep 2025
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts filed
AccountsLast accounts made up date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzQzNDc1ODMxOWFkaXF6a2N4
Published 06 Sep 2024 09:21
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
CHROMASKIN: Minimally-Invasive Interstitial Fluid Sensing Materials for Semi-Permanent Dermal Readouts
1 May 2026 to 31 Jan 2027
CHROMASKIN is an innovative dermal biosensing technology that enables people to monitor key health markers using a small, painless microneedle patch. When placed on the skin, the microneedle penetrate the skin dissolve and deposit tiny colour-changing particles into the dermis. These particles interact with the body's interstitial fluid and change colour ...
FREEDOM: Female REproductive Empowerment and DOse Management
1 Oct 2024 to 31 Mar 2026
The **FREEDOM-Patch** (**F**emale **RE**productive **E**mpowerment and **DO**se **M**anagement Patch) project is a collaborative effort between CipherX Technologies and the Stevens Group at the University of Oxford. This 18-month feasibility project aims to develop a next-generation female contraceptive device utilising advanced microneedle-array patch te...
Development of a novel microneedle based technology with integrated delivery confirmation to enhance self-administration reliability of needle-free vaccines.
1 Aug 2024 to 30 Apr 2025
The healthcare and vaccine delivery sectors, while essential, face significant challenges in ensuring global vaccine accessibility and minimising wastage. These challenges are compounded by the reliance on cold chain logistics and the necessity for skilled healthcare personnel for vaccine administration. In response, CipherX and Nemaura have embarked on a...